Watch Out, AbbVie: Johnson & Johnson Is Nipping at Your Heels

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 13 October, 2016 by The TZ Newswire Staff

Watch Out, AbbVie: Johnson & Johnson Is Nipping at Your Heels

Gettyimages

Image source: Getty Images.

AbbVie‘s (NYSE: ABBV) Humira reigns as the most successful treatment around for several autoimmune diseases, including rheumatoid arthritis and Crohn’s disease. In 2015, the drug generated a whopping $14 billion in sales.

See also
- Next Article Bank of Mom and Dad still funding millennial finances like phones and clothing
- Previous Article Samsung offers financial incentives to stem Note 7 bleeding
Editorial Calender

October 2016

M T W T F S S

1 2

3 4 5 6 7 8 9

10 11 12 13 14 15 16

17 18 19 20 21 22 23

24 25 26 27 28 29 30

31

« Sep Nov »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 13 October, 2016 by The TZ Newswire Staff

Watch Out, AbbVie: Johnson & Johnson Is Nipping at Your Heels

See also

Editorial Calender

Recent Tags